199284 Implementation of a National Pharmacogenomics Education Program (PharmGenEd)

Tuesday, November 10, 2009: 4:33 PM

Grace M. Kuo, PharmD, MPH , Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA
Pharmacogenomics aims to increase the response rate of drug therapy and decrease the events of adverse drug reactions. Pharmacogenomics may help us focus on safe and effective drug management to provide personalized medicine by delivering therapy with the right drug at the right dose to the right patient. Currently, however, pharmacogenomics education materials are not readily available to healthcare professionals. Furthermore, there appears to be a gap between healthcare providers' knowledge and the expectations of patients regarding pharmacogenomic testing. The proposed program, “Pharmacogenomics Education Program: Bridging the Gap between Science and Practice” (PharmGenEd), is an evidence-based pharmacogenomics education program designed for healthcare professionals and students. The objective of the PharmGenEd is to increase awareness about current knowledge of the validity and utility of pharmacogenomic tests and the potential implications of benefits and harms from use of the tests. Our target population exceeds 100,000 healthcare professionals and students. Program team works closely with CDC and incorporates evidence-based recommendations from the EGAPP Working Group, the Food and Drug Administration, and the published literature authored by pharmacogenomics experts. Specifically, PharmGenEd aims to: 1) Develop educational curriculum focusing on pharmacogenomics primer concepts and clinical applications in concentrated therapeutic areas; 2) Disseminate the educational curriculum to pharmacists, students, and other healthcare professionals using live and online methods, including web-based virtual communities with “pubcasts” (using technologies similar to YouTube and Facebook for scientists); and 3) Evaluate outcomes and processes of the education program in various audience groups and using different delivery methods.

Learning Objectives:
1. Describe a national pharmacogenomics education program (PharmGenEd) 2. List collaborating organizations and program activities 3. Identify platforms for continuing education programs and shared curriculum 4. Formulate PharmGenEd program implementation plans and measurement matrix 5. Assess PharmGenEd program progress

Keywords: Genetics, Education

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the Program Director of the national educational program " Pharmacogenomics Education program: Bridging the Gap between Science and Practice", funded by CDC (2008 - 2011). Previously, I have served on the planning committee on 2 national conferences: 1) Embracing the PBRN Model to Improve the Medication Use Process (held in 2007 funded by AHRQ); 2) Primary Care Ambulatory Health Information Technology and Patient Safety Conference (held in 2008 funded by AHRQ). I served as a speaker and helped designed several educational programs, including: 1) Reimbursement for Cognitive Services: Case Studies in Success; Reimbursement for Cognitive Services: Family Medicine Clinic. American Society of Health-system Pharmacist (ASHP) mid-year conference. Atlanta, Georgia, December 11, 2002; 2) Cultural Competence in Primary Care: Implications in the Care of the Asian Patient Fostering Health Literacy and Cultural Competency in Patient Care (# 204-000-04-216-L04). ASHP Midyear Clinical Meeting and Exhibits. Orlando, FL, December 7, 2004; 3) Colleagues in Research: Practice Based Research--Current Practices and Lessons Learned. American Pharmacist Association 155th Annual Meeting and Exposition. Atlanta, GA, March 2007.
Any relevant financial relationships? Yes

Name of Organization Clinical/Research Area Type of relationship
CDC Pharmacogenomics Education Program Funding recipient
Med Info Service, Inc. Medication safety Stock Ownership

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.